KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Accumulated Expenses (2016 - 2023)

Esperion Therapeutics filings provide 7 years of Other Accumulated Expenses readings, the most recent being $25.0 million for Q4 2023.

  • On a quarterly basis, Other Accumulated Expenses rose 89.32% to $25.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $25.0 million, a 89.32% increase, with the full-year FY2023 number at $25.0 million, up 89.32% from a year prior.
  • Other Accumulated Expenses hit $25.0 million in Q4 2023 for Esperion Therapeutics, up from $13.2 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $30.4 million in Q4 2021 to a low of $3.2 million in Q1 2020.
  • Median Other Accumulated Expenses over the past 5 years was $10.9 million (2019), compared with a mean of $13.0 million.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 249.04% in 2019 and later crashed 56.58% in 2022.
  • Esperion Therapeutics' Other Accumulated Expenses stood at $11.9 million in 2019, then surged by 108.83% to $24.8 million in 2020, then rose by 22.67% to $30.4 million in 2021, then crashed by 56.58% to $13.2 million in 2022, then soared by 89.32% to $25.0 million in 2023.
  • The last three reported values for Other Accumulated Expenses were $25.0 million (Q4 2023), $13.2 million (Q4 2022), and $30.4 million (Q4 2021) per Business Quant data.